Fresenius Medical Care’s Game-Changing HDF Treatment Slashes Mortality by 23%—Will the U.S. Catch Up?

Fresenius Medical Care (FMC) reported its fourth-quarter 2024 financial results, showcasing both achievements and areas needing attention as the company continues its strategic transformation. The results reflect a period of organizational change and progress, with tangible financial improvements but also challenges that persist. Beginning with the positives, FMC reported a notable 7.4% organic revenue growth in the fourth quarter, driven by both its Care Delivery and Care Enablement segments. The company highlighted its strategic transformation program, FME25, as a significant contributor to its operating income growth of 18% for 2024. The transformation program has already yielded €567 million in sustainable savings, surpassing initial targets and now aiming for €750 million by the end of 2025. This has supported improved margins across segments despite lower-than expected U.S. dialysis volume growth.